Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study

Authors:

Abstract
Background: Prognosis in extensive-stage disease small cell lung cancer (ED-SCLC) is poor and patients (pts) commonly relapse within months of completing first-line platinum-based chemotherapy (CT). Investigation into a potential role for immune checkpoint inhibitors in SCLC treatment is supported by good scientific rationale, principally the high mutational burden associated with the disease. We report preliminary efficacy of anti-PD-L1 mAb durvalumab (D) plus anti-CTL4 mAb tremelimumab (T) in pts with platinum-refractory/resistant ED-SCLC, as assessed in Arm A of BALTIC (NCT02937818), a Phase II, multi-arm, signal-searching study.